Five-day course of Molnupiravir effective and safe for non-pregnant and unvaccinated COVID-19 adult patients: Study Read more
SMS Pharmaceuticals receives non-exclusive licence to manufacture and supply Molnupiravir through MPP Read more
Merck allocates three million courses of Molnupiravir to be provided in first half of 2022 for use in LMICs Read more